Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 33,431 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Stage 2 Clear all
Not listed Phase 1 Interventional Accepts healthy volunteers

Comparison of Tetravalent Dengue Virus Purified Inactivated Vaccine and Tetravalent Dengue Virus Live Attenuated Vaccine

NCT03141138
View directory record Official record
Conditions
Dengue Virus
Interventions
TDENV-PIV, TDENV-LAV F17
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 42 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 30, 2026, 10:12 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder

NCT03317158
View directory record Official record
Conditions
Urothelial Carcinoma, Bladder Cancer
Interventions
Durvalumab (Cohort 1-3), External Beam Radiotherapy (EBRT), Bacillus Calmette-Guérin (BCG), Gemcitabine, Docetaxel, Tremelimumab, Durvalumab (Cohort 4/5), To be determined, Intravesical NAI (Cohorts 6-7), Subcutaneous NAI (Cohort 8)
Drug · Radiation · Biological + 1 more
Lead sponsor
Noah Hahn, M.D.
Other
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
9
States / cities
Phoenix, Arizona • Indianapolis, Indiana • Iowa City, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 30, 2026, 10:12 AM EDT
Completed Not applicable Interventional Results available

Radiation Therapy During Surgery in Treating Older Women With Invasive Breast Cancer

NCT00182728
View directory record Official record
Conditions
Breast Cancer
Interventions
surgery, therapy, radiation therapy
Procedure · Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
48 Years to 120 Years · Female only
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 30, 2026, 10:12 AM EDT
Recruiting Phase 1Phase 2 Interventional

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

NCT03556228
View directory record Official record
Conditions
Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Mesothelioma, Esophageal Cancer, Any Solid Tumors Progressed After a Prior Immunotherapy, Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC, Salivary Gland Carcinomas, Head and Neck Cancers - Salivary Gland, Head and Neck Cancers - Nasopharyngeal, Head and Neck Cancers - Throat, Small Cell Lung Cancer ( SCLC ), Lung Cancer (Locally Advanced or Metastatic), Head and Neck Cancers - Tonsils, Head and Neck Cancers Hypopharynx, Head and Neck Cancers Larynx, Head and Neck Cancers Lip, Head and Neck Cancers Nasopharynx, Head and Neck Cancers Oral Cavity, Head and Neck Cancers, Head and Neck Cancers Oropharynx, Head and Neck Cancers Trachea
Interventions
VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg)
Drug
Lead sponsor
VM Oncology, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
14
States / cities
Santa Rosa, California • Hartford, Connecticut • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 30, 2026, 10:12 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

NCT07062965
View directory record Official record
Conditions
Breast Cancer
Interventions
PF-07248144, Fulvestrant, Everolimus, Exemestane
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
215
States / cities
Anchorage, Alaska • Chandler, Arizona • Gilbert, Arizona + 150 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 30, 2026, 10:12 AM EDT
Terminated Phase 2 Interventional Results available

18F-DCFPyL Positron Emission Tomography (PET) in Intermediate or High Risk Prostate Cancer

NCT04727736
View directory record Official record
Conditions
Prostate Cancer
Interventions
18F-DCFPyL
Drug
Lead sponsor
Ashok Muthukrishnan
Other
Eligibility
18 Years and older · Male only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 15, 2024 · Synced Oct 30, 2026, 10:12 AM EDT
Recruiting Phase 1Phase 2 Interventional

Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

NCT06780111
View directory record Official record
Conditions
Esophageal Squamous Cell Carcinoma
Interventions
Pembrolizumab, I-DXd, Leucovorin, Levoleucovorin, 5-Fluorouracil (5-FU), Oxaliplatin, Sacituzumab tirumotecan, Rescue Medication
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 30, 2026, 10:12 AM EDT
Completed Phase 2 Interventional Results available

Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy

NCT00104871
View directory record Official record
Conditions
Insular Thyroid Cancer, Recurrent Thyroid Cancer, Stage II Follicular Thyroid Cancer, Stage II Papillary Thyroid Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Papillary Thyroid Cancer
Interventions
Bortezomib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
9
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 30, 2026, 10:12 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study to Evaluate the Efficacy and Safety of JointStem in Treatment of Osteoarthritis

NCT02674399
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
JointStem, Synvisc-One
Drug
Lead sponsor
Nature Cell Co. Ltd.
Industry
Eligibility
22 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Santa Monica, California • Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Oct 30, 2026, 10:12 AM EDT
Active, not recruiting No phase listed Observational

Long Term Follow up of Children Enrolled in the REDvent Study

NCT03709199
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult, Ventilator-Induced Lung Injury, Neurocognitive Dysfunction, Quality of Life, Respiration Disorders
Interventions
Ventilation Inhomogeneity, Diaphragm Ultrasound, Respiratory Inductance Plethysmography, Spirometry, Functional Residual Capacity, MIP/MEP, 6 minute walk test, Neurocognitive Testing, Emotional Health Assessment, Health Related Quality of Life, Functional Status, Respiratory Status Questionnaire
Diagnostic Test
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
1 Month to 18 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Oct 30, 2026, 10:12 AM EDT
Completed Phase 2 Interventional Results available

Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Participants With Attention-deficit Hyperactivity Disorder (ADHD)

NCT04081363
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Centanafadine
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
9 Years to 12 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2023 · Synced Oct 30, 2026, 10:12 AM EDT
Enrolling by invitation No phase listed Observational

Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) Precision Medicine Phase 2 Option 1

NCT04602806
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
5
States / cities
San Francisco, California • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 30, 2026, 10:12 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)

NCT03555149
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Regorafenib, Atezolizumab, Imprime PGG, Bevacizumab, Isatuximab, Selicrelumab, Idasanutlin, AB928, LOAd703
Drug · Genetic
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
6
States / cities
Duarte, California • New Haven, Connecticut • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 30, 2026, 10:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers

NCT02743455
View directory record Official record
Conditions
Yellow Fever, Yellow Fever Immunisation
Interventions
ISA-720, MVA Smallpox Vaccine, MVA-BN Yellow Fever Vaccine, Placebo, YF Vax 17D Strain
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Iowa City, Iowa • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 30, 2026, 10:12 AM EDT
Completed Phase 3 Interventional

A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight

NCT06066528
View directory record Official record
Conditions
Obesity, Diabetes Mellitus, Type 2
Interventions
Survodutide, Placebo
Combination Product
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
34
States / cities
Anniston, Alabama • Phoenix, Arizona • Spring Valley, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 30, 2026, 10:12 AM EDT
Active, not recruiting Phase 1 Interventional Results available

Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma

NCT04477200
View directory record Official record
Conditions
Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Astrocytoma, Grade IV, Newly Diagnosed Glioblastoma, Newly Diagnosed Gliosarcoma, Newly Diagnosed Astrocytoma, Grade IV
Interventions
Mycophenolate Mofetil, Radiation Therapy, Re-resection (as part of standard of care), Temozolomide
Drug · Radiation · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 30, 2026, 10:12 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy of Short-Course Antimicrobial Treatment for Children With Acute Otitis Media and Impact on Resistance

NCT01511107
View directory record Official record
Conditions
Acute Otitis Media
Interventions
Amoxicillin-Clavulanate, 10 days, Amoxicillin-Clavulanate, 5 days
Drug
Lead sponsor
Alejandro Hoberman
Other
Eligibility
6 Months to 23 Months
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Bardstown, Kentucky • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 30, 2026, 10:12 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of Combination Therapy to Treat Uncomplicated Obesity

NCT00364871
View directory record Official record
Conditions
Obesity
Interventions
naltrexone and bupropion SR
Drug
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
7
States / cities
San Diego, California • Augusta, Georgia • Lexington, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2008 · Synced Oct 30, 2026, 10:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effects of Epetraborole on the QT Interval in Healthy Adult Subjects

NCT05995444
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Epetraborole and matching placebo, Epetraborole, Placebo, Moxifloxacin
Drug
Lead sponsor
AN2 Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 30, 2026, 10:12 AM EDT
Completed Phase 1 Interventional

A Study of GDC-0941 in Participants With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable

NCT00876109
View directory record Official record
Conditions
Solid Cancers
Interventions
GDC-0941
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
3
States / cities
Scottsdale, Arizona • Boston, Massachusetts • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 30, 2026, 10:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple Ascending Dose Study of ETC-1002 in Subjects With Mild Dyslipidemia

NCT01105598
View directory record Official record
Conditions
Mild Dyslipidemia
Interventions
ETC-1002 or placebo
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Oct 30, 2026, 10:12 AM EDT
Terminated Phase 1 Interventional Results available

A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)

NCT03948763
View directory record Official record
Conditions
Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Colorectal Neoplasms
Interventions
V941, Pembrolizumab
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
10
States / cities
Gilbert, Arizona • Duarte, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 30, 2026, 10:12 AM EDT
Completed Phase 2 Interventional Results available

Phase II Randomized Trial of Bethesda Protocol Compared to Cambridge Method for Detection of Early Stage Gastric Cancer in CDH1 Mutation Carriers

NCT04535414
View directory record Official record
Conditions
Gastric Cancer, Gastric Neoplasms, Gastric Adenocarcinoma
Interventions
Cellvizio (Registered trademark) Real-Time In Vivo Cellular Imaging Platform with Confocal Miniprobes, Olympus Graphics Interchange Format (GIF) 190 endoscope, Gastric mucosal biopsy
Device · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 17, 2025 · Synced Oct 30, 2026, 10:12 AM EDT
Suspended Phase 1 Interventional

Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma

NCT06922604
View directory record Official record
Conditions
Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
Interventions
Biospecimen Collection, Computed Tomography, Glofitamab, Lumbar Puncture, Magnetic Resonance Imaging, Obinutuzumab, Positron Emission Tomography
Procedure · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 30, 2026, 10:12 AM EDT